产品
编 号：F614491
分子式：C20H21F3O5S
分子量：430.44
分子式：C20H21F3O5S
分子量：430.44
产品类型
规格
价格
是否有货
结构图
CAS No: 212188-60-8
产品详情
生物活性：
BAY 38-7271 is selective and highly potent and cannabinoid CB1/CB2 receptor agonist, with Kis of 1.85 nM and 5.96 nM for recombinant human CB1 receptor and CB2 receptor, respectively. BAY 38-7271 has strong neuroprotective properties.
体内研究：
BAY 38-7271 (Ed50 = 0.02 mg/kg; i.v. and 0.5 mg/kg; i.p.) induces a potent and dose-de-pendent reduction in core body temperature.BAY 38-7271 has low physical dependence liability and is not essentially different from that of other cannabinoid CB1 receptor agonists.BAY 38-7271 (1-1000 ng/kg/h; i.v. infusion; for 4 hours) shows neuroprotective efficacy in the rat SDH model.BAY 38-7271 also has neuroprotective efficacy in models of transient and permanent occlusion of the middle cerebral artery and brain edema models.Animal Model:Wistar rat ,TBI rat models (acute subdural hematoma, SDH)
Dosage:1 ng/kg/h, 10 ng/kg/h, 100 ng/kg/h, 1000 ng/kg/h
Administration:Intravenous infusion, for 4 hours
Result:Reduced the mean infarct volume.
体外研究：
BAY 38-7271 shows only minor interactions at the micromolar range with other binding sites such as adenosine A3 receptor (IC50 = 7.5 μM), peripheral GABAA benzodiazepine receptor (IC50 = 971 nM), melatonin ML1 receptor (IC50 = 3.3 μM), and at the monoamine transporter (IC50 = 1.7 μM).
BAY 38-7271 is selective and highly potent and cannabinoid CB1/CB2 receptor agonist, with Kis of 1.85 nM and 5.96 nM for recombinant human CB1 receptor and CB2 receptor, respectively. BAY 38-7271 has strong neuroprotective properties.
体内研究：
BAY 38-7271 (Ed50 = 0.02 mg/kg; i.v. and 0.5 mg/kg; i.p.) induces a potent and dose-de-pendent reduction in core body temperature.BAY 38-7271 has low physical dependence liability and is not essentially different from that of other cannabinoid CB1 receptor agonists.BAY 38-7271 (1-1000 ng/kg/h; i.v. infusion; for 4 hours) shows neuroprotective efficacy in the rat SDH model.BAY 38-7271 also has neuroprotective efficacy in models of transient and permanent occlusion of the middle cerebral artery and brain edema models.Animal Model:Wistar rat ,TBI rat models (acute subdural hematoma, SDH)
Dosage:1 ng/kg/h, 10 ng/kg/h, 100 ng/kg/h, 1000 ng/kg/h
Administration:Intravenous infusion, for 4 hours
Result:Reduced the mean infarct volume.
体外研究：
BAY 38-7271 shows only minor interactions at the micromolar range with other binding sites such as adenosine A3 receptor (IC50 = 7.5 μM), peripheral GABAA benzodiazepine receptor (IC50 = 971 nM), melatonin ML1 receptor (IC50 = 3.3 μM), and at the monoamine transporter (IC50 = 1.7 μM).
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备